Practical Insights Into Improving Adherence to Metformin Therapy in Patients With Type 2 Diabetes

Christofides, Elena A.

doi:10.2337/cd18-0063

Cited by 17 publications

(11 citation statements)

References 27 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings suggest that if patients are supported to continue taking their metformin beyond 3 months, they are likely to remain on it successfully at least for 1 year. A number of strategies, including enhanced patient‐provider communication, e‐Health interventions, and using extended‐release formulations have been shown to improve adherence to metformin 29 …”

Section: Discussionmentioning

confidence: 99%

First‐line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence and associated costs

Campbell

Ogundeji

et al. 2021

Diabet Med

View full text Add to dashboard Cite

Aims To use real‐world prescription data from Alberta, Canada to: (a) describe the prescribing patterns for initial pharmacotherapy for those with newly diagnosed uncomplicated type 2 diabetes; (b) describe medication‐taking behaviours (adherence and persistence) in the first year after initiating pharmacotherapy; and (c) explore healthcare system costs associated with prescribing patterns. Methods We employed a retrospective cohort design using linked administrative datasets from 2012 to 2017 to define a cohort of those with uncomplicated incident diabetes. We summarized the initial prescription patterns, adherence and costs (healthcare and pharmaceutical) over the first year after initiation of pharmacotherapy. Using multivariable regression, we determined the association of these outcomes with various sociodemographic characteristics. Results The majority of individuals for whom metformin was indicated as first‐line therapy received a prescription for metformin monotherapy (89%). Older individuals, those with higher baseline A1C and those with no comorbidities, were most likely to be started on non‐metformin agents. Adherence with the initially prescribed regimen was suboptimal overall, with nearly half (48%) being non‐adherent over the first year. One‐third of those who started metformin discontinued it in the first 3 months. Those started on non‐metformin agents had roughly twice the healthcare costs, and five to seven times higher medication costs, compared to those started on metformin, in the first year after starting therapy. Conclusions With the addition of new classes of medications, healthcare providers who look after those with type 2 diabetes have more pharmaceutical options than ever. Most individuals continue to be prescribed metformin monotherapy. However, adherence is suboptimal, and drops off considerably within the first 3 months.

show abstract

Section: Discussionmentioning

confidence: 99%

First‐line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence and associated costs

Campbell

Ogundeji

et al. 2021

Diabet Med

View full text Add to dashboard Cite

show abstract

“…Strategies to optimise adherence to metformin will be needed, especially given the asymptomatic nature of non-diabetic hyperglycaemia. 102 Some trials in progress in populations with non-diabetic hyperglycaemia, described above, are using the XR formulation of metformin, which may support better adherence to therapy than the immediate-release formulation, based on clinical experience in people with type 2 diabetes. 103…”

Section: Adherencementioning

confidence: 99%

Metformin for diabetes prevention: update of the evidence base

Hostalek

Campbell

2021

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…Metformin (1500–3000 mg/day for 6 months) is recognized as a well-tolerated anti-diabetic drug [78]. Importantly, several studies revealed that metformin decreases the risk of many cancers including hepatocellular carcinoma and prostate cancer [79,80].…”

Section: The Synergistic Effect Of Curcumin Combination Chemotherapymentioning

confidence: 99%

Curcumin Combination Chemotherapy: The Implication and Efficacy in Cancer

2019

View full text Add to dashboard Cite

Many chemotherapeutic drugs have been used for the treatment of cancer, for instance, doxorubicin, irinotecan, 5-fluorouracil, cisplatin, and paclitaxel. However, the effectiveness of chemotherapy is limited in cancer therapy due to drug resistance, therapeutic selectivity, and undesirable side effects. The combination of therapies with natural compounds is likely to increase the effectiveness of drug treatment as well as reduce the adverse outcomes. Curcumin, a polyphenolic isolated from Curcuma longa, belongs to the rhizome of Zingiberaceae plants. Studies from in vitro and in vivo revealed that curcumin exerts many pharmacological activities with less toxic effects. The biological mechanisms underlying the anticancer activity of co-treatment curcumin and chemotherapy are complex and worth to discuss further. Therefore, this review aimed to address the molecular mechanisms of combined curcumin and chemotherapy in the treatment of cancer. The anticancer activity of combined nanoformulation of curcumin and chemotherapy was also discussed in this study. Taken together, a better understanding of the implication and underlying mechanisms of action of combined curcumin and chemotherapy may provide a useful approach to combat cancer diseases.

show abstract

Practical Insights Into Improving Adherence to Metformin Therapy in Patients With Type 2 Diabetes

Abstract: Metformin is a biguanide that is highly effective at lowering both basal and prandial glucose levels by reducing hepatic glucose production, increas

Cited by 17 publications

References 27 publications

First‐line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence and associated costs

First‐line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence and associated costs

Metformin for diabetes prevention: update of the evidence base

Curcumin Combination Chemotherapy: The Implication and Efficacy in Cancer

Contact Info

Product

Resources

About